Biora Therapeutics announced that the company has been granted an extension to regain compliance with Nasdaq listing requirements. The Nasdaq Hearings Panel granted Biora’s request for continued listing on The Nasdaq Stock Market, subject to the company’s compliance with the $50 million market value of listed securities rule and $1 bid price requirements for continued listing on The Nasdaq Global Market by November 7, 2024.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOR:
- Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Biora Therapeutics reports Q2 EPS (4c), consensus (45c)
- Biora Therapeutics Restructures Debt and Issues New Securities
- Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Biora Therapeutics Announces Funding Agreement with Existing Investors